This is an Open Access article licensed under the terms of the Creative Commons AttributionNonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only. Glabrae Rhizoma attenuates hyperuricemia, but its mechanism is unclear. Our previous study demonstrated that uric acid could induce the generation of reactive oxygen species(ROS), which subsequently cause endothelial dysfunction. Therefore, we focused on the oxidative stress process. In this study, we would use LC-MS and bioinformatic analysis to investigate the underlying mechanism. Methods: We utilized LC-MS to reveal the differential protein expression in the kidneys of rats in the hyperuricemia group and the Smilacis Glabrae Rhizoma treatment group and then subjected the differentially expressed proteins to bioinformatic analysis. We also determined the serum ROS level of the two groups. According the above results, we built our hypothesis and performed in vitro experiments to validate this hypothesis. Results: We found that catalase was upregulated in the group treated with Smilacis Glabrae Rhizoma, and the level of reactive oxygen species was higher in the hyperuricemia group. Thus, we speculated that Smilacis Glabrae Rhizoma could alleviate oxidative stress by upregulating catalase. In vitro experiments, we found that high concentrations of uric acid reduced catalase expression in endothelial cells, which was alleviated by Smilacis Glabrae Rhizoma and resulted in a reduction of reactive oxygen species. Knockdown of catalase led to an increase in reactive oxygen species. Conclusion: We demonstrated that Smilacis Glabrae Rhizoma could alleviate the oxidative stress caused by hyperuricemia by upregulating catalase treatment of hyperuricemia.
Introduction
hyperuricemia is an independent risk factor for chronic kidney disease (CKD) and cardiovascular disease (CVD) [1] [2] [3] [4] . Therefore, investigating ways to control serum uric acid levels has become a topic of great interest.
Interest in the use of traditional Chinese medicine (TCM) for the treatment of hyperuricemia has grown in recent years [5, 6] . Many TCM remedies contain Smilacis Glabrae Rhizoma (SGR), which belongs to the Smilacaceae family and the Smilax genus.
easing joint movement in the TCM literature, including the Compendium of Materia Medica and the State Pharmacopoeia of the People's Republic of China. Hu et al reported that a Simiao pill could reduce elevated serum uric acid (UA) levels and alleviate renal injury caused by hyperuricemia [7] . However, the mechanism of its protective effects on renal function under hyperuricemic conditions is not known. It has been demonstrated that the that high concentrations of uric acid could cause endothelial dysfunction by generating has also been reported that high concentrations of uric acid could induce renal failure by damaging endothelial cells [15] , but the underlying mechanism remains unclear. Given the above research, we hypothesized that, to some extent, hyperuricemia causes renal injury by increasing the ROS that damage endothelial cells. SGR could play a protective role for the kidneys by diminishing ROS production, thereby ameliorating endothelial damage. In this study, we used label-free quantitative liquid chromatography mass spectrometry (Label-free LC-MS/MS) to analyze protein expression in the kidneys of control rats and hyperuricemic rats that were treated with SGR. Of the differentially expressed proteins, catalase is noteworthy because it is responsible for the degradation of hydrogen peroxide [16] , and it is a protective enzyme that is present in nearly all animal cells [17] [18] [19] . In this study, we also demonstrated that catalase could be upregulated by SGR and that it reduced the generation of ROS that were induced by high concentrations of uric acid in vitro.
Materials and Methods

Materials and reagents
The dried rhizome of SGR was purchased from the Beijing Tong Ren Tang Pharmacy (Beijing, China). Ethyl alcohol and methanol (analytical grade) were purchased from the Beijing Chemical Reagent Company. Allopurinol (its purity exceeded 99.2%, as determined by HPLC), uric acid and oxonic acid were purchased from Sigma-Aldrich (St Louis MO. USA). Assay kits for uric acid ROS were obtained from Jiancheng Biotech (Nanjing, China).
Establishment of hyperuricemic rat models
The animal protocol was reviewed and approved by the Institutional Animal Care and Use Committee of the Chinese PLA General Hospital. Sprague Dawley (SD) rats, obtained from the Experimental Animal Center of Academy of Military Medical Sciences (China), were housed in temperature-controlled cages on a 12 h light-dark cycle and were given free access to water and normal chow. After 1 week of breeding for adaptation, the rats were grouped into control (n=8) and hyperuricemic (n=8) groups. The rats were injected intraperitoneally with 250 mg/kg·d of oxonic acid potassium salt (Sigma) and 250 mg/kg· d of uric acid (Sigma). Fourteen days after modeling, the levels of UA in the blood were evaluated. Then, the rats were orally administered a solution with or without 1 mL of SGR (1 g/mL) every day for the subsequent four weeks.
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LC-MS and data processing
LC-MS was performed as described previously [22, 23] . Continuum LC-MS data were processed and searched using Protein Lynx Global Server software, version 2.4 (Waters Corp.), with Expression software, version 2 (Waters Corp.). During the data preparation, the low-and elevated-energy thresholds were set at using the protein expression module in PLGS software, version 2.5. The entire data set of differentially
The data analysis was completed by http://www.uniprot.org and http://www.capitalbio. com/zh-hans/ support/MAS3.
Pathway analysis
according to KEGG and Genemap [24, 25] . Fisher's exact test and the x 2 test were used to classify the GO category, and the false discovery rate (FDR) was calculated to correct the P-value. A smaller FDR indicated , where N k refers to the number of Fisher's test P-values that are less than the x 2 test P-values. We computed P-values for the pathways of all enrichment, Re, was given by: Re = (n f / n)/(N f / N), where n f is the number of differential proteins within the particular category, n is the total number of proteins within the same category, N f is the number of differential proteins in the entire microarray, and N is the total number of proteins in the LC-MS.
Cell culture
Human umbilical vein endothelial cells (HUVECs) were purchased from ATCC (No. CRL-1730) and were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) at 37 incubator in an atmosphere containing 5% CO 2 .
Western blot assay RIPA lysis buffer (containing 50 mmol/L Tris-HCl at pH 7.5, 150 mmol/L NaCl, 0.5% deoxycholate, used to extract the proteins. The tissue lysate was taken to determine the concentrations of proteins to a PVDF membrane, which was kept overnight in a 5% no-milk solution at 4 after Ponceau S staining. The membrane was incubated in primary antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA). The blots were developed with an ECL reagent (Santa Cruz Biotechnologies) according to the manufacturer's (Bio-rad).
Small interfering RNA (siRNA) transfection
Catalase siRNA (100 nM, sc-29204, Santa Cruz Biotechnology) was transfected into HUVECs using the RNAi MAX transfection reagent, according to the manufacturer's instructions (Invitrogen). A non-silencing siRNA was used as the negative control. Forty-eight hours after transfection, the cells were starved for 16 h and then were treated with or without UA.
Measurement of total intracellular ROS
The changes in intracellular ROS were detected with CM-H 2 system mounted on an inverted microscope and equipped with an argon-krypton laser. For studies using CM-H 2 DCFDA, an excitation wavelength of 488 nm (argon laser) and an emission wavelength of 515 nm were used. higher than in the control cells. Nevertheless, when cells were treated with a medium that can damage endothelial cells, which are important for maintaining kidney function. It was reported that the kidney damage caused by hyperuricemia was primarily due to oxidative process was altered in the SGR treatment group. Therefore, we speculated that SGR might exert its effects by inhibiting the oxidative stress process induced by hyperuricemia. Based on gene-pathway and GO-protein network results, we found that, among the differentially expressed proteins, catalase was related to the oxidative stress process and was upregulated approximately 6.4-fold more in the SGR treatment group compared with the HUA group. We an important component of ROS, and therefore reduce oxidative stress. It was demonstrated that hyperuricemia could increase ROS generation systemically [38] ; therefore, we sought to determine whether SGR could reduce ROS generation systemically. We examined the serum ROS of the two groups and found that the serum ROS level of the SGR treatment group was lower than that of the hyperuricemia group. Thus, we speculated that SGR could increase catalase expression, which reduced ROS systemically in hyperuricemic mice, indicating that SGR might reduce the oxidative stress caused by hyperuricemia. To validate this hypothesis, we performed an in vitro experiment. Because endothelial cells are among the main targets of oxidative stress caused by hyperuricemia in the kidneys, we used them in our experiment. We determined the expression level of catalase and the total ROS level under high uric acid concentration conditions with and without SGR. The results demonstrated that a high concentration of uric acid reduced the expression level of catalase in endothelial cells, and this decrease could be alleviated by SGR, leading to a reduction in ROS. The knockdown of have found that SGR attenuated hyperuricemia by promoting the excretion of uric acid [39] , but it remains unknown whether there is a mechanism that does not rely on increasing alleviate the oxidative stress caused by hyperuricemia by increasing the expression of on the kidneys.
In conclusion, we demonstrated that SGR could alleviate the oxidative stress caused by application for SGR in the treatment of hyperuricemia.
